Vanessa Jensen

Chair

The University of Texas MD Anderson Cancer Center
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (10)

Supplementary Table 1: Genomic and biomarker data of zanidatamab co-clinical trial xenograft models. Genomic and biomarker data of zanidatamab co-clinical trial xenograft models. Patient biomarkers/NGS has four categories: (+), (-), N/A, and Gain Supplementary Table 2: Event-free survival and relative treatment-to-control ratios for co-clinical trial PDXs. Event-free survival and relative treatment-to-control ratios for co-clinical trial PDXs. Supplementary Table 3. Event-free survival of PDXs compared to patient response. Event-free survival of PDXs compared to patient response. Supplementary Table 4. Immunohistochemistry antibodies.

Year:

2024

Supplementary Figure 1: HER2 status of patients and corresponding PDX models. HER2 expression was assessed by IHC and ERBB2 amplification status by FISH and NGS. FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; NGS, next-generation sequencing. Alterations represents genomic alterations in available CLIA genomic testing on archival patient samples (matching PDX hosts). CLIA results were not available for patients matching PDX.003.025, PDX.003.263, and PDX.003.230. Supplementary Figure 2: Actionable gene alterations in patient biopsies compared to the alteration in the resulting PDX as determined by whole exome sequencing on both. Supplementary Figure 3: Cell viability assay with crizotinib. Cells were treated with crizotinib at serial dilutions for 72 hours. Following SRB staining, IC50 was calculated using CalcuSyn. Supplementary Figure 4. In vivo assessment of zanidatamab in combination with BET inhibitor JQ1. 50 mg/kg JQ1 had no antitumor effects as single agent and did not add benefit when combined with 16 mg/kg zanidatamab.

Year:

2024

Supplementary Table 1: Genomic and biomarker data of zanidatamab co-clinical trial xenograft models. Genomic and biomarker data of zanidatamab co-clinical trial xenograft models. Patient biomarkers/NGS has four categories: (+), (-), N/A, and Gain Supplementary Table 2: Event-free survival and relative treatment-to-control ratios for co-clinical trial PDXs. Event-free survival and relative treatment-to-control ratios for co-clinical trial PDXs. Supplementary Table 3. Event-free survival of PDXs compared to patient response. Event-free survival of PDXs compared to patient response. Supplementary Table 4. Immunohistochemistry antibodies.

Year:

2024

Supplementary Figure 1: HER2 status of patients and corresponding PDX models. HER2 expression was assessed by IHC and ERBB2 amplification status by FISH and NGS. FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; NGS, next-generation sequencing. Alterations represents genomic alterations in available CLIA genomic testing on archival patient samples (matching PDX hosts). CLIA results were not available for patients matching PDX.003.025, PDX.003.263, and PDX.003.230. Supplementary Figure 2: Actionable gene alterations in patient biopsies compared to the alteration in the resulting PDX as determined by whole exome sequencing on both. Supplementary Figure 3: Cell viability assay with crizotinib. Cells were treated with crizotinib at serial dilutions for 72 hours. Following SRB staining, IC50 was calculated using CalcuSyn. Supplementary Figure 4. In vivo assessment of zanidatamab in combination with BET inhibitor JQ1. 50 mg/kg JQ1 had no antitumor effects as single agent and did not add benefit when combined with 16 mg/kg zanidatamab.

Year:

2024

Supplementary Table 1: Genomic and biomarker data of zanidatamab co-clinical trial xenograft models. Genomic and biomarker data of zanidatamab co-clinical trial xenograft models. Patient biomarkers/NGS has four categories: (+), (-), N/A, and Gain Supplementary Table 2: Event-free survival and relative treatment-to-control ratios for co-clinical trial PDXs. Event-free survival and relative treatment-to-control ratios for co-clinical trial PDXs. Supplementary Table 3. Event-free survival of PDXs compared to patient response. Event-free survival of PDXs compared to patient response. Supplementary Table 4. Immunohistochemistry antibodies.

Year:

2024

Zanidatamab is a bispecific human epidermal growth factor receptor 2 (HER2)-targeted antibody that has demonstrated antitumor activity in a broad range of HER2-amplified/expressing solid tumors. We determined the antitumor activity of zanidatamab in patient-derived xenograft (PDX) models developed from pretreatment or postprogression biopsies on the first-in-human zanidatamab phase I study (NCT02892123). Of 36 tumors implanted, 19 PDX models were established (52.7% take rate) from 17 patients. Established PDXs represented a broad range of HER2-expressing cancers, and in vivo testing demonstrated an association between antitumor activity in PDXs and matched patients in 7 of 8 co-clinical models tested. We also identified amplification of MET as a potential mechanism of acquired resistance to zanidatamab and demonstrated that MET inhibitors have single-agent activity and can enhance zanidatamab activity in vitro and in vivo . These findings provide evidence that PDXs can be developed from pretreatment biopsies in clinical trials and may provide insight into mechanisms of resistance. Significance: We demonstrate that PDXs can be developed from pretreatment and postprogression biopsies in clinical trials and may represent a powerful preclinical tool. We identified amplification of MET as a potential mechanism of acquired resistance to the HER2 inhibitor zanidatamab and MET inhibitors alone and in combination as a therapeutic strategy. This article is featured in Selected Articles from This Issue, p. 695

Year:

2024

Supplementary Figure 1: HER2 status of patients and corresponding PDX models. HER2 expression was assessed by IHC and ERBB2 amplification status by FISH and NGS. FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; NGS, next-generation sequencing. Alterations represents genomic alterations in available CLIA genomic testing on archival patient samples (matching PDX hosts). CLIA results were not available for patients matching PDX.003.025, PDX.003.263, and PDX.003.230. Supplementary Figure 2: Actionable gene alterations in patient biopsies compared to the alteration in the resulting PDX as determined by whole exome sequencing on both. Supplementary Figure 3: Cell viability assay with crizotinib. Cells were treated with crizotinib at serial dilutions for 72 hours. Following SRB staining, IC50 was calculated using CalcuSyn. Supplementary Figure 4. In vivo assessment of zanidatamab in combination with BET inhibitor JQ1. 50 mg/kg JQ1 had no antitumor effects as single agent and did not add benefit when combined with 16 mg/kg zanidatamab.

Year:

2024

Supplementary Table 1: Genomic and biomarker data of zanidatamab co-clinical trial xenograft models. Genomic and biomarker data of zanidatamab co-clinical trial xenograft models. Patient biomarkers/NGS has four categories: (+), (-), N/A, and Gain Supplementary Table 2: Event-free survival and relative treatment-to-control ratios for co-clinical trial PDXs. Event-free survival and relative treatment-to-control ratios for co-clinical trial PDXs. Supplementary Table 3. Event-free survival of PDXs compared to patient response. Event-free survival of PDXs compared to patient response. Supplementary Table 4. Immunohistochemistry antibodies.

Year:

2024

Supplementary Figure 1: HER2 status of patients and corresponding PDX models. HER2 expression was assessed by IHC and ERBB2 amplification status by FISH and NGS. FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; NGS, next-generation sequencing. Alterations represents genomic alterations in available CLIA genomic testing on archival patient samples (matching PDX hosts). CLIA results were not available for patients matching PDX.003.025, PDX.003.263, and PDX.003.230. Supplementary Figure 2: Actionable gene alterations in patient biopsies compared to the alteration in the resulting PDX as determined by whole exome sequencing on both. Supplementary Figure 3: Cell viability assay with crizotinib. Cells were treated with crizotinib at serial dilutions for 72 hours. Following SRB staining, IC50 was calculated using CalcuSyn. Supplementary Figure 4. In vivo assessment of zanidatamab in combination with BET inhibitor JQ1. 50 mg/kg JQ1 had no antitumor effects as single agent and did not add benefit when combined with 16 mg/kg zanidatamab.

Year:

2024

Zanidatamab is a bispecific human epidermal growth factor receptor 2 (HER2)-targeted antibody that has demonstrated antitumor activity in a broad range of HER2-amplified/expressing solid tumors. We determined the antitumor activity of zanidatamab in patient-derived xenograft (PDX) models developed from pretreatment or postprogression biopsies on the first-in-human zanidatamab phase I study (NCT02892123). Of 36 tumors implanted, 19 PDX models were established (52.7% take rate) from 17 patients. Established PDXs represented a broad range of HER2-expressing cancers, and in vivo testing demonstrated an association between antitumor activity in PDXs and matched patients in 7 of 8 co-clinical models tested. We also identified amplification of MET as a potential mechanism of acquired resistance to zanidatamab and demonstrated that MET inhibitors have single-agent activity and can enhance zanidatamab activity in vitro and in vivo . These findings provide evidence that PDXs can be developed from pretreatment biopsies in clinical trials and may provide insight into mechanisms of resistance. Significance: We demonstrate that PDXs can be developed from pretreatment and postprogression biopsies in clinical trials and may represent a powerful preclinical tool. We identified amplification of MET as a potential mechanism of acquired resistance to the HER2 inhibitor zanidatamab and MET inhibitors alone and in combination as a therapeutic strategy. This article is featured in Selected Articles from This Issue, p. 695

Year:

2024

Collaborators (7)

Anil Korkut

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Paula Pohlmann

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Milind Javle

PROFESSOR

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Maria Gabriela Raso

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jaffer A. Ajani

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Shubham Pant

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details